Combinations targeting PD-1/PD-L1 and VEGF/VEGFR pathways—which aim to reprogram tumor vasculature and remodel the immune microenvironment—have shown synergistic efficacy but are often accompanied by substantial vascular-related toxicities. The gene discussed is PDCD1; the disease is neoplasm.